Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate  compared to...

Related Keywords

United Kingdom ,Canada ,London ,City Of ,Russia ,Minnesota ,United States ,Israel ,Montreal ,Quebec ,Olmsted County ,Ukraine ,Gaza ,Israel General ,British ,American ,Americans ,Russian ,David Bharucha ,A John Camm ,Kim Fox ,Prevention Statistics Committee ,Clinical Sciences Research Institute ,Cardiology Clinical Academic Group ,Milestone Pharmaceuticals ,George University ,American Heart Association Council On Epidemiology ,Drug Administration ,Exchange Commission ,American Heart Association ,Nasdaq ,Milestone Pharmaceuticals Inc ,Featured Science ,Heart Association ,Scientific Sessions ,John Camm ,British Heart Foundation Emeritus Professor ,Clinical Cardiology ,Chief Medical Officer ,Controlled Study ,Etripamil Nasal Spray ,Science Session ,Treatment Satisfaction Questionnaire ,Analyst Call ,Atrial Fibrillation ,Rapid Ventricular ,New Drug Application ,Looking Statements ,Private Securities Litigation Reform Act ,Quarterly Report ,Heart Association Council ,Statistics Committee ,Stroke Statistics Subcommittee ,Heart Disease ,Report From ,Vice President ,Canada Newswire ,Markets ,